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2020 changed our lives. For too many it was the end of their life. 
For all of us, it heralded a new reality. During 2020 my social media 
feed was full of people wishing the year would end. I thought that 
little would change. The virus was not suddenly going to disappear. 
However, unprecedented advances in vaccine science meant that 
we now have a new weapon with which to fight the virus – and not 
just one, but several, all of which have proven efficacy against SARS-
CoV-2, albeit with differing levels of effectiveness against mild disease, 
but most appearing to provide pretty good protection against severe 
disease and death. Hold that thought.
After a lot of fiddling about, our government finally took the 
task of vaccine procurement seriously, and many of the concerns 
and criticisms that I,[1] and our major infectious disease and vaccine 
experts,[2] were levelling at government have now been addressed. And 
all seemed to be about to happen, albeit with continuing concerns 
about roll-out beyond the ‘first phase’ to front-line health workers. But 
then, the sting in the tail – the variants, of which there are many, but 
of particular concern here with the spread of 501Y.V2, the so-called 
South African variant. By now I am sure everyone knows that a small 
trial with relatively young volunteers has shown that the AstraZeneca 
vaccine, which was about to be rolled out to our health workers, only 
offers around 22% protection against mild disease caused by this 
variant.[3] Protection against severe disease and death in these cases 
is not yet known. However, we do know that the vaccine is safe, and 
further studies may well show that there is still protection against 
severe disease and death. Our Minister of Health has subsequently 
assured us that we have sufficient access to the alternative Johnson & 
Johnson vaccine to administer it to our health workers on a research 
basis. This started on 17 February 2021 in Khayelitsha in the Western 
Cape, with the President and Minister of Health, along with front-
line health workers, among the first to receive the vaccine. And our 
President publicly announced in his State of the Nation speech that 
20 million doses of the Pfizer vaccine will be delivered from the end of 
March, 12 million of these from the COVAX facility.[4]
Another very encouraging sign is the reappearance of Professors 
Madhi and Gray on government platforms, signifying that finally our 
leading experts are being listened to. Hopefully, the Department of 
Health will now be led by science rather than by politics, at least as 
far as vaccines are concerned.
However, what is starting to become clear is a changing perspec-
tive around how to control COVID-19. The perspective around 
achieving herd immunity using vaccines is changing. The rapid 
emergence of SARS-CoV-2 variants around the world (and these 
are the ones we know about), in the UK, here in South Africa and in 
Brazil, makes it very likely that without full global vaccination, herd 
immunity may never be achieved. This is because of the spread of 
variants, which arise because of levels of population immunity that 
are too low to fully protect against new infections (and re-infections), 
but which are acting as drivers of mutations that allow the virus to 
escape that immunity, including in vaccines. In essence, new variants 
‘knock vaccine efficacy down a rung or two’.[5] So a vaccine that may 
originally have protected against infection with the original virus 
may now protect only against symptomatic infection. In other words, 
you still get a nasty dose of a flu-like illness. But, at the same time, 
these vaccines are likely to protect against severe illness and death 
in all but the most compromised of people. That seems like a pretty 
good outcome, given that global vaccination is all but impossible with 
the constraints resulting from the Global North buying up just about 
all the stocks of vaccines, and vaccine production and distribution 
failing to keep up with demand anyway. 
The thinking now is that we will never achieve full herd 
immunity. Well, places like New Zealand might, but they will have 
to remain closed to the rest of the world for all time to sustain 
that. While this may be a scary prospect, given how COVID-19 
has rampaged through the population in the past 12 months, 
there is a lot to be learned from looking at the biology of the other 
coronaviruses – the four that cause the common cold, in particular. 
A model developed by Lavine et al.[6] analysing the trajectory of 
SARS-CoV-2 into endemicity suggests that there will eventually 
be a shift in the age distribution of primary infections to younger 
age groups, depending on the speed of viral spread. Essentially, this 
model suggests that infection-blocking immunity wanes rapidly, 
but that disease-reducing immunity is long-lived. So we will end up 
with SARS-CoV-2 established in the population, but moving mainly 
among younger people, who are less affected, and, once the endemic 
phase is reached, with primary exposure in childhood, SARS-
CoV-2 may become no more virulent than 
the common cold. We are still a long way 
from that. However, using vaccines that, 
while they may not prevent mild disease 
and so transmission of the virus, still 
protect against severe disease and deaths, 
is a very good start. Don’t throw away the 
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